Open Access

Low dose dinaciclib enhances doxorubicin‑induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways

  • Authors:
    • Hailong Tang
    • Li Xu
    • Xue Liang
    • Guangxun Gao
  • View Affiliations

  • Published online on: September 20, 2018     https://doi.org/10.3892/ol.2018.9474
  • Pages: 6608-6614
  • Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multiple myeloma (MM) is a hematological malignancy that lacks a cure. However, novel combination therapy is a current anti‑MM strategy. Doxorubicin (DOX) is a type of anthracycline which is a first‑line chemotherapeutic for treating MM and induces senescence in many types of cancer. Dinaciclib is a potent, small molecule CDK inhibitor with promise for treating several types of cancer in I/II phase clinical trials. In the present study the anticancer effects and underlying mechanisms of dinaciclib combined with DOX in MM RPMI‑8226 cells were investigated. Results indicated that DOX induced cell viability inhibition, cell cycle arrest and senescence. Furthermore, DOX resulted in increased alterations in DNA damage‑related proteins such as p‑ATM, p‑Chk2, p‑p53, p21 and γH2AX, but not p16. Notably, the combination of dinaciclib and DOX inhibited cell growth and promoted senescence by transforming the suppressive effects of the ATM/Chk2/p53/p21 signaling pathway and enhancing the p16 signaling pathway. Thus, low‑dose dinaciclib enhanced anti‑MM effects mediated by DOX via transformation of p21‑p16 signaling pathways, leading to accelerated senescence, but not apoptosis. The present findings suggest this approach may be a promising therapeutic strategy for the treatment of MM.
View Figures
View References

Related Articles

Journal Cover

November-2018
Volume 16 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tang H, Xu L, Liang X and Gao G: Low dose dinaciclib enhances doxorubicin‑induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways. Oncol Lett 16: 6608-6614, 2018
APA
Tang, H., Xu, L., Liang, X., & Gao, G. (2018). Low dose dinaciclib enhances doxorubicin‑induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways. Oncology Letters, 16, 6608-6614. https://doi.org/10.3892/ol.2018.9474
MLA
Tang, H., Xu, L., Liang, X., Gao, G."Low dose dinaciclib enhances doxorubicin‑induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways". Oncology Letters 16.5 (2018): 6608-6614.
Chicago
Tang, H., Xu, L., Liang, X., Gao, G."Low dose dinaciclib enhances doxorubicin‑induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways". Oncology Letters 16, no. 5 (2018): 6608-6614. https://doi.org/10.3892/ol.2018.9474